stalevo and Dyskinesia--Drug-Induced

Accumulating data on experience of long therapy with levodopa revealed the pathomorphosis of clinical presentations of Parkinson's disease during its progression, in particular, described, the occurrence of motor fluctuations and levodopa-induced dyskinesias. In later stages of the illness, these disturbances attracted special attention of both the patient, and the attending, worsening quality of a life of patients. The article describes the main issues of the pathogenesis of this type of disorders and the currently available strategies for its treatment. We present our own experience of treatment motor fluctuations by means of the combined three-component medical product stalevo containing levodopa, carbidopa and entacapone.

Topics: Aged; Carbidopa; Catechols; Drug Combinations; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Parkinson Disease

The triple combination of levodopa, DDCI and entacapone (Stalevo) is used to treat motor complication in patients with Parkinson's disease. In this study we summarized the clinical data of our patients treated with Stalevo for the longest period. We can concluded, that after switching to Stalevo due to wearing off, the average levodopa doses were lower then before and the motor complications were milder. After 3 years of Stalevo therapy the levodopa doses were increased but still did not reach the average doses before introducing Stalevo. After switching the patients' general well-being was improved as indicated by the visual analogue scale. In summary, the Stalevo treatment is safe and effective for long run and improves the patients' quality of life.

Topics: Aged; Antiparkinson Agents; Carbidopa; Catechols; Drug Combinations; Drug Resistance; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Middle Aged; Pain Measurement; Parkinson Disease; Quality of Life; Severity of Illness Index; Time Factors; Treatment Outcome